BioNTech SE

22UA.DE·XETRA·Healthcare
Compare
81.60+1.55 (+1.94%)today
At close: Oct 21, 5:35 PM CEST · May be delayed up to 15 min · EUR

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close80.05
Open81.00
Day range80.6582.15
52-week range68.30105.70
Off day high−0.67%
Off 52-week high−22.80%
Volume19.72K
Avg. volume (3M)41.21K
Market cap20.50B
EPS (TTM)-6.71
Forward P/E—
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)1.25
Shares outstanding251.20M
Short interest—
Earnings dateNov 3, 2026
Analyst target—
Profit margin−63.64%

Against its peers

Compare in full ›
22UA.DE GMAB ROIV 1877.HK BINV.ST IBRX
Market cap 20.50B 24.33B 26.58B 17.65B 1.35B 9.16B
P/E (TTM) — 31.2 — — — —
Forward P/E — 26.1 -21.4 86.2 -5.2 -54.0
Price/book 1.2 4.0 6.3 2.5 4.3 -8.7
Dividend yield — — — — — —
1-year change −12.23% +30.58% +94.43% −37.10% −17.59% +271.61%
Today +1.94% +1.28% +5.38% +3.74% −4.87% −1.48%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Latest news

All 22UA.DE news ›
The National Tribune·Positive

BioNTech MRNA Manufacturing Facility Opens

La Trobe University is now home to one of the world’s leading biopharmaceutical companies, with the official opening of BioNTech’s state-of-the-art, clinical-scale mRNA manufacturing and research facility at the University’s campus in…

@clin_trials·Negative

BioNTech's BNT113 Misses PFS Goal in Head and Neck Cancer Trial

BioPharm International connects biopharmaceutical professionals with scientific and business insights on biopharma R&D, manufacturing & regulatory issues. BioNTech announced October 13, 2026, that the phase 2/3 AHEAD-MERIT trial did not…

The Epoch Times·Negative

BioNTech’s mRNA Cancer Vaccine Falls Short of Goal in Trial

A messenger ribonucleic acid (mRNA) vaccine against cancer failed to meet a primary goal of a late-stage clinical trial, the shot’s manufacturer said on Oct. 13. The experimental vaccine, known as BNT113, fell short of its primary endpoint…

From articles in the 4Search news index.

In the news

53mentions in 30 days
53with it in the headline
Mixedsentiment

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 53 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use.